13.50
Schlusskurs vom Vortag:
$13.62
Offen:
$13.47
24-Stunden-Volumen:
1.60M
Relative Volume:
0.42
Marktkapitalisierung:
$1.50B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-6.6832
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
+8.55%
1M Leistung:
+24.10%
6M Leistung:
-8.74%
1J Leistung:
-28.76%
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TXG
10 X Genomics Inc
|
13.51 | 1.60B | 631.73M | -239.78M | -33.45M | -2.02 |
![]()
VEEV
Veeva Systems Inc
|
290.73 | 46.61B | 2.86B | 780.66M | 1.20B | 4.72 |
![]()
TEM
Tempus Ai Inc
|
63.34 | 10.57B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
60.56 | 11.13B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
95.23 | 8.42B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
37.23 | 6.33B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
2024-06-03 | Fortgesetzt | Jefferies | Hold |
2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
2023-12-14 | Eingeleitet | Guggenheim | Buy |
2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
2023-05-10 | Eingeleitet | Barclays | Overweight |
2023-03-31 | Eingeleitet | Stephens | Overweight |
2023-02-02 | Eingeleitet | UBS | Neutral |
2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
2021-10-15 | Fortgesetzt | Cowen | Outperform |
2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
2021-03-15 | Eingeleitet | William Blair | Outperform |
2020-12-02 | Eingeleitet | Goldman | Neutral |
2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
2020-07-10 | Eingeleitet | Stifel | Buy |
2020-03-05 | Eingeleitet | Guggenheim | Buy |
2020-01-07 | Eingeleitet | Citigroup | Buy |
2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
2019-10-07 | Eingeleitet | Cowen | Outperform |
2019-10-07 | Eingeleitet | JP Morgan | Overweight |
2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
What analysts say about 10x Genomics Inc. stockOutperformance with explosive growth - Autocar Professional
Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know - Yahoo Finance
Is 10x Genomics Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com
10x Genomics Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com
What drives 10x Genomics Inc. stock priceBreakout profit opportunities - jammulinksnews.com
10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study - Agency for Science, Technology and Research
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know - Yahoo Finance
10x Genomics Ends UPC Patent Fight With Bruker - Law360
10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery - the-scientist.com
Why 10x Genomics Inc. stock attracts strong analyst attentionFree Market Sentiment Analysis - beatles.ru
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know - Yahoo Finance
10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025 - BioSpace
10x Genomics Reaches Analyst Target Price - Nasdaq
10x Genomics(TXG) Soars 7.88% on Strong Q1 Earnings - AInvest
10x Genomics Insiders Sold US$768k Of Shares Suggesting Hesitancy - 富途牛牛
10x Genomics, Inc.(NasdaqGS: TXG) dropped from Russell 1000 Value Index - MarketScreener
10x Genomics, Inc.(NasdaqGS: TXG) dropped from Russell 1000 Dynamic Index - MarketScreener
10x Genomics (TXG) Receives a Hold from Bank of America Securities - The Globe and Mail
10x Genomics (TXG) Analyst Maintains Rating but Raises Price Target | TXG Stock News - GuruFocus
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG) - Yahoo Finance
11 Best Genomics Stocks to Buy According to Hedge Funds - Insider Monkey
Revenues Not Telling The Story For 10x Genomics, Inc. (NASDAQ:TXG) After Shares Rise 31% - simplywall.st
10x Genomics Inc (TXG) Trading 4.12% Higher on Jun 18 - GuruFocus
UPC Backs Sales Ban On Kits Infringing 10x Genomics Patent - Law360
Delta, Macy's, CECO Environmental, RadNet, and 10x Genomics Shares Skyrocket, What You Need To Know - Yahoo Finance
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Brown Capital Management Small Company Fund Sold 10x Genomics (TXG) Due to Fundamental Concerns - Insider Monkey
10x Genomics, Inc. (TXG) Stock Analysis: Evaluating A 28% Potential Upside For Investors - DirectorsTalk Interviews
Forecasting The Future: 7 Analyst Projections For 10x Genomics - Benzinga
Long Read Sequencing Market Key Players Analysis10X Genomics, - openPR.com
10x Genomics, Inc. (NASDAQ:TXG) Stock Holdings Increased by Deutsche Bank AG - Defense World
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
10 X Genomics Inc-Aktie (TXG) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Hindson Benjamin J. | See Remarks |
May 22 '25 |
Sale |
8.30 |
7,485 |
62,120 |
448,374 |
Taich Adam | Chief Financial Officer |
May 22 '25 |
Sale |
8.30 |
4,044 |
33,562 |
331,588 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):